DCM
KNTE
DAFNA Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-50,000
| Closed | -$119K | – | 83 |
|
|
2023
Q4 | $119K | Sell |
50,000
-55,179
| -52% | -$131K | 0.03% | 75 |
|
|
2023
Q3 | $147K | Buy |
105,179
+25,000
| +31% | +$35K | 0.05% | 73 |
|
|
2023
Q2 | $243K | Sell |
80,179
-829
| -1% | -$2.51K | 0.07% | 69 |
|
|
2023
Q1 | $506K | Buy |
81,008
+10,000
| +14% | +$62.5K | 0.15% | 60 |
|
|
2022
Q4 | $433K | Sell |
71,008
-7,066
| -9% | -$43.1K | 0.12% | 64 |
|
|
2022
Q3 | $933K | Sell |
78,074
-146,377
| -65% | -$1.75M | 0.25% | 61 |
|
|
2022
Q2 | $2.83M | Buy |
224,451
+76,300
| +52% | +$962K | 0.77% | 36 |
|
|
2022
Q1 | $1.67M | Buy |
148,151
+41,698
| +39% | +$469K | 0.43% | 56 |
|
|
2021
Q4 | $1.89M | Hold |
106,453
| – | – | 0.47% | 46 |
|
|
2021
Q3 | $2.45M | Buy |
106,453
+52,038
| +96% | +$1.2M | 0.65% | 42 |
|
|
2021
Q2 | $1.27M | Buy |
54,415
+1,500
| +3% | +$34.9K | 0.27% | 68 |
|
|
2021
Q1 | $1.65M | Sell |
52,915
-15,206
| -22% | -$474K | 0.39% | 56 |
|
|
2020
Q4 | $2.71M | Buy |
+68,121
| New | +$2.71M | 0.81% | 30 |
|